Abstract
In anticipation of US Food and Drug Administration (FDA) approval of nirsevimab (single-dose monoclonal antibody for seasonal immunization against respiratory syncytial virus [RSV]), codes 90380–90381 were approved by the American Medical Association Current Procedural Terminology® Editorial Panel in May 2023 and released on June 30, 2023. The codes will became effective immediately on FDA approval of the vaccine. There are several things to know about coding for provision and administration of nirsevimab, including the following: Differentiating codes for nirsevimab and palivizumab The appropriate administration code for monoclonal antibody immunization Reporting nirsevimab administration and other services on the same date
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
